Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 226

The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.

The independent effects of eicosapentaenoic acid and docosahexaenoic acid on cardiovascular risk factors in humans

Mori, Trevor A, Woodman, Richard J · 2006 · Current Opinion in Clinical Nutrition & Metabolic Care

Abstract

PURPOSE OF REVIEW: This review details the independent effects of purified eicosapentaenoic acid and docosahexaenoic acid on cardiovascular risk factors in humans. We report data from the recent literature and our own controlled clinical trials which compared the independent effects of these fatty acids in individuals at increased risk of cardiovascular disease, namely overweight hyperlipidaemic men and treated-hypertensive, type 2 diabetic men and women. We discuss the biological effects of these fatty acids and the potential mechanisms through which they may affect cardiovascular disease risk factors. RECENT FINDINGS: A cardioprotective effect for omega3 fatty acids is supported by prospective studies demonstrating an inverse association between fish intake and coronary heart disease mortality. Data from secondary prevention trials support a reduction in ventricular fibrillation as a primary mechanism for the decreased incidence of myocardial infarction. Clinical trials and experimental studies have shown that omega3 fatty acids have many other potentially important antiatherogenic and antithrombotic effects. Omega-3 fatty acids lower blood pressure and heart rate, improve dyslipidaemia, reduce inflammation, and improve vascular and platelet function. These favourable effects have until recently been primarily attributed to the omega3 fatty acid eicosapentaenoic acid, which is present in large amounts in fish oil. Controlled studies in humans now demonstrate that docosahexaenoic acid, although often present in lower quantities, has equally important anti-arrhythmic, anti-thrombotic and anti-atherogenic effects. SUMMARY: Available evidence strongly suggests that eicosapentaenoic acid and docosahexaenoic acid have differing haemodynamic and anti-atherogenic properties. The effects of the two fatty acids may also differ depending on the target population.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/01.mco.0000214566.67439.58

Cites

19 of 19 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 19 references

Research works printed but not linked: 68

  1. Zhang, 1999, Fish consumption and mortality from all causes, ischemic heart disease, and stroke: an ecological study, Prev Med, 28, 520, 10.1006/pmed.1998.0472 · DOI · Paper page
  2. Marckmann, 1999, Fish consumption and coronary heart disease mortality. A systematic review of prospective cohort studies, Eur J Clin Nutr, 53, 585, 10.1038/sj.ejcn.1600832 · DOI · Paper page
  3. Leaf, 1996, Prevention of cardiac sudden death by N-3 fatty acids: a review of the evidence, J Intern Med, 240, 5, 10.1046/j.1365-2796.1996.449803000.x · DOI
  4. Harris, 1997, n-3 fatty acids and serum lipoproteins: human studies, Am J Clin Nutr, 65, 1645S, 10.1093/ajcn/65.5.1645S · DOI · Paper page
  5. Bao, 1998, Effects of dietary fish and weight reduction on ambulatory blood pressure in overweight hypertensives, Hypertension, 32, 710, 10.1161/01.HYP.32.4.710 · DOI · Paper page
  6. Mori, 2000, Differential effects of eicosapentaenoic acid and docosahexaenoic acid on vascular reactivity of the forearm microcirculation in hyperlipidemic, overweight men, Circulation, 102, 1264, 10.1161/01.CIR.102.11.1264 · DOI · Paper page
  7. Mori, 2004, ω3 Fatty acids and inflammation, Curr Atherosclerosis Rep, 6, 461, 10.1007/s11883-004-0087-5 · DOI · Paper page
  8. Knapp, 1997, Dietary fatty acids in human thrombosis and hemostasis, Am J Clin Nutr, 65, 1687S, 10.1093/ajcn/65.5.1687S · DOI · Paper page
  9. Dunstan, 1999, A randomised, controlled study of the effects of aerobic exercise and dietary fish on coagulation and fibrinolytic factors in type 2 diabetics, Thromb Haemostasis, 81, 367, 10.1055/s-0037-1614479 · DOI
  10. Calder, 2001, Polyunsaturated fatty acids, inflammation, and immunity, Lipids, 36, 1007, 10.1007/s11745-001-0812-7 · DOI · Paper page
  11. Mori, 1997, Interactions between dietary fat, fish, and fish oils and their effects on platelet function in men at risk of cardiovascular disease, Arterioscler Thromb Vasc Biol, 17, 279, 10.1161/01.ATV.17.2.279 · DOI · Paper page
  12. Mori, 2004, The effect of fish and fish oil-derived omega-3 fatty acids on lipid oxidation, Redox Report, 9, 193, 10.1179/135100004225005200 · DOI
  13. Bang, 1971, Plasma lipid and lipoprotein pattern in Greenlandic West-coast Eskimos, Lancet, 1, 1143, 10.1016/S0140-6736(71)91658-8 · DOI · Paper page
  14. Woodman, 2003, Effects of purified eicosapentaenoic acid and docosahexaenoic acid on platelet, fibrilolytic and vascular function in Type 2 diabetic patients, Atherosclerosis, 166, 85, 10.1016/S0021-9150(02)00307-6 · DOI · Paper page
  15. Nestel, 2002, The n-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid increase systemic arterial compliance in humans, Am J Clin Nutr, 76, 326, 10.1093/ajcn/76.2.326 · DOI · Paper page
  16. Park, 2002, EPA, but not DHA, decreases mean platelet volume in normal subjects, Lipids, 37, 941, 10.1007/s11745-006-0984-1 · DOI
  17. Mori, 1999, Docosahexaenoic acid but not eicosapentaenoic acid lowers ambulatory blood pressure and heart rate in humans, Hypertension, 34, 253, 10.1161/01.HYP.34.2.253 · DOI · Paper page
  18. Halvorsen, 1997, The effect of highly purified eicosapentaenoic and docosahexaenoic acids on monocyte phagocytosis in man, Lipids, 32, 935, 10.1007/s11745-997-0120-2 · DOI
  19. Grimsgaard, 1998, Effects of highly purified eicosapentaenoic acid and docosahexaenoic acid on hemodynamics in humans, Am J Clin Nutr, 68, 52, 10.1093/ajcn/68.1.52 · DOI · Paper page
  20. Yamamoto, 1995, Improvement of coronary vasomotion with eicosapentaenoic acid does not inhibit acetylcholine-induced coronary vasospasm in patients with variant angina, Jap Circ J, 59, 608, 10.1253/jcj.59.608 · DOI
  21. Agren, 1997, Hemostatic factors and platelet aggregation after a fish-enriched diet or fish oil or docosahexaenoic acid supplementation, Prostagland Leuk Essent Fatty Acids, 57, 419, 10.1016/S0952-3278(97)90421-X · DOI
  22. Agren, 1996, Fish diet, fish oil and docosahexaenoic acid rich oil lower fasting and postprandial plasma lipid levels, Eur J Clin Nutr, 50, 765
  23. Hamazaki, 1996, Docosahexaenoic acid-rich fish oil does not affect serum lipid concentrations of normolipidemic young adults, J Nutr, 126, 2784
  24. Hirai, 1989, Effect of oral administration of highly purified eicosapentaenoic acid and docosahexaenoic acid on platelet function and serum lipids in hyperlipidemic patients, Adv Prost Thromb Leuk Res, 19, 627
  25. Hirai, 1987, Effect of supplementation of highly purified eicosapentaenoic acid and docosahexaenoic acid on hemostatic function in healthy subjects, Adv Prost Thromb Leuk Res, 17B, 838
  26. von Schacky, 1985, Metabolism and effects on platelet function of the purified eicosapentaenoic and docosahexaenoic acids in humans, J Clin Invest, 76, 2446, 10.1172/JCI112261 · DOI · Paper page
  27. Saito, 1999, An assessment of appropriate vitamin E content in fish oil capsules as estimated by lipid peroxide and vitamin E levels in human blood, J Clin Biochem Nutr, 26, 35, 10.3164/jcbn.26.35 · DOI
  28. Tagawa, 1999, Long-term treatment with eicosapentaenoic acid augments both nitric oxide-mediated and non-nitric oxide-mediated endothelium-dependent forearm vasodilatation in patients with coronary artery disease, J Cardiovasc Pharm, 33, 633, 10.1097/00005344-199904000-00017 · DOI
  29. Nakamura, 1998, Effects of eicosapentaenoic acids on remnant-like particles, cholesterol concentrations and plasma fatty acid composition in patients with diabetes mellitus, In Vivo, 12, 311
  30. Harris, 1997, n-3 fatty acids and urinary excretion of nitric oxide metabolites in humans, Am J Clin Nutr, 65, 459, 10.1093/ajcn/65.2.459 · DOI
  31. Nishikawa, 1997, Effects of eicosapentaenoic acid (EPA) on prostacyclin production in diabetics: GC/MS analysis of PGI2 and PGI3 levels, Method Find Exp Clin, 19, 429
  32. Shinozaki, 1996, The long-term effect of eicosapentaenoic acid on serum levels of lipoprotein (a) and lipids in patients with vascular disease, J Atherosclerosis Thromb, 2, 107, 10.5551/jat1994.2.107 · DOI
  33. Tsuruta, 1996, Effect of purified eicosapentaenoate ethyl ester on fibrinolytic capacity in patients with stable coronary artery disease and lower extremity ischaemia, Coronary Artery Dis, 7, 837, 10.1097/00019501-199611000-00008 · doi:10.1097/00019501-199611000-00008
  34. Miwa, 1996, Thin-layer chromatography and high-performance liquid chromatography for the assay of fatty acid compositions of individual phospholipids in platelets from non-insulin-dependent diabetes mellitus patients: effect of eicosapentaenoic acid ethyl ester administration, J Chromatogr B, 677, 217, 10.1016/0378-4347(95)00445-9 · doi:10.1016/0378-4347(95)00445-9
  35. Shimizu, 1995, Long-term effect of eicosapentaenoic acid ethyl (EPA-E) on albuminuria of non-insulin dependent diabetic patients, Diab Res Clin Prac, 28, 35, 10.1016/0168-8227(95)01056-J · DOI
  36. Saga, 1994, Changes in platelet count and mean volume of platelet after administration of icosapentaenoic acid ethyl-ester, and factors that may affect those changes, Jpn J Geriatrics, 31, 538, 10.3143/geriatrics.31.538 · doi:10.3143/geriatrics.31.538
  37. Westerveld, 1993, Effects of low-dose EPA-E on glycemic control, lipid profile, lipoprotein(a), platelet aggregation, viscosity, and platelet and vessel wall interaction in NIDDM, Diabetes Care, 16, 683, 10.2337/diacare.16.5.683 · DOI
  38. Nozaki, 1992, Effects of purified eicosapentaenoic acid ethyl ester on plasma lipoproteins in primary hypercholesterolemia, Int J Vitam Nutr Res, 62, 256
  39. Wojenski, 1991, Eicosapentaenoic acid ethyl ester as an antithrombotic agent: comparison to an extract of fish oil, Biochim Biophys Acta, 1081, 33, 10.1016/0005-2760(91)90246-E · DOI
  40. Croset, 1990, Functions and tocopherol content of blood platelets from elderly people after low intake of purified eicosapentaenoic acid, Thromb Res, 57, 1, 10.1016/0049-3848(90)90190-N · DOI
  41. Hamazaki, 1990, Reduction in microalbuminuria in diabetics by eicosapentaenoic acid ethyl ester, Lipids, 25, 541, 10.1007/BF02537161 · DOI
  42. Hawthorne, 1990, High dose eicosapentaenoic acid ethyl ester: effects on lipids and neutrophil leukotriene production in normal volunteers, Br J Clin Pharmacol, 30, 187, 10.1111/j.1365-2125.1990.tb03764.x · DOI
  43. Kamido, 1988, Lipid composition of platelets from patients with atherosclerosis: effect of purified eicosapentaenoic acid ethyl ester administration, Lipids, 23, 917, 10.1007/BF02536337 · DOI
  44. Tamura, 1987, Anti-thrombotic and anti-atherogenic action of eicosapentaenoic acid, Jpn Circ J, 51, 471, 10.1253/jcj.51.471 · doi:10.1253/jcj.51.471
  45. Lands, 1985, Relationship of thromboxane generation to the aggregation of platelets from humans: effects of eicosapentaenoic acid, Prostaglandins, 30, 819, 10.1016/0090-6980(85)90010-3 · doi:10.1016/0090-6980(85)90010-3
  46. Tamura, 1985, Effects of eicosapentaenoic acid on hemostatic function and serum lipids in humans, Adv Prost Thromb Leuk Res, 15, 265
  47. Nagakawa, 1983, Effect of eicosapentaenoic acid on the platelet aggregation and composition of fatty acid in man. A double blind study, Atherosclerosis, 47, 71, 10.1016/0021-9150(83)90073-4 · DOI
  48. Terano, 1983, Effect of oral administration of highly purified eicosapentaenoic acid on platelet function, blood viscosity and red cell deformability in healthy human subjects, Atherosclerosis, 46, 321, 10.1016/0021-9150(83)90181-8 · DOI · Paper page
  49. Ferretti, 1998, Dietary docosahexaenoic acid reduces the thromboxane/prostacyclin synthetic ratio in humans, J Nutr Biochem, 9, 88, 10.1016/S0955-2863(97)00172-1 · DOI
  50. Conquer, 1997, Dietary docosahexaenoic acid as a source of eicosapentaenoic acid in vegetarians and omnivores, Lipids, 32, 341, 10.1007/s11745-997-0043-y · DOI
  51. Nelson, 1997, The effect of dietary docosahexaenoic acid on plasma lipoproteins and tissue fatty acid composition in humans, Lipids, 32, 1137, 10.1007/s11745-997-0146-5 · DOI
  52. Nelson, 1997, The effect of dietary docosahexaenoic acid on platelet function, platelet fatty acid composition, and blood coagulation in humans, Lipids, 32, 1129, 10.1007/s11745-997-0145-6 · DOI
  53. Kobayashi, 1987, Changes of hemorrheological properties by highly purified DHA in normal subjects, Adv Prost Thromb Leuk Res, 17B, 866
  54. Hulthe, 2000, The metabolic syndrome, LDL particle size, and atherosclerosis: the Atherosclerosis and Insulin Resistance (AIR) study, Arterioscler Thromb Vasc Biol, 20, 2140, 10.1161/01.ATV.20.9.2140 · DOI · Paper page
  55. Lahdenpera, 1996, Regulation of low-density lipoprotein particle size distribution in NIDDM and coronary disease: importance of serum triglycerides, Diabetologia, 39, 453, 10.1007/BF00400677 · DOI
  56. Morris, 1993, Does fish oil lower blood pressure: a meta-analysis of controlled trials, Circulation, 88, 523, 10.1161/01.CIR.88.2.523 · DOI · Paper page
  57. Mclennan, 1996, The cardiovascular protective role of docosahexaenoic acid, Eur J Pharmacol, 300, 83, 10.1016/0014-2999(95)00861-6 · DOI · Paper page
  58. Mori, 1992, Differential effect of aspirin on platelet aggregation in IDDM, Diabetes, 41, 261, 10.2337/diab.41.3.261 · DOI
  59. Akiba, 2000, Involvement of lipoxygenase pathway in docosapentaenoic acid-induced inhibition of platelet aggregation, Biol Pharm Bull, 23, 1293, 10.1248/bpb.23.1293 · DOI
  60. Swann, 1990, Enrichment of platelet phospholipids with eicosapentaenoic acid and docosahexaenoic acid inhibits thromboxane A2/prostaglandin H2 receptor binding and function, J Biol Chem, 265, 21692, 10.1016/S0021-9258(18)45795-X · DOI
  61. Abeywardena, 1991, Differential effects of dietary fish oil on myocardial prostaglandin I2 and thromboxane A2 production, Am J Physiol Heart Circ Physiol, 260, H379, 10.1152/ajpheart.1991.260.2.H379 · DOI
  62. Mori, 1999, Fish oils: dyslipidaemia and glycaemic control in diabetes, Prac Diab Int, 16, 223, 10.1002/pdi.1960160712 · DOI
  63. Berge, 1999, In contrast with docosahexaenoic acid, eicosapentaenoic acid and hypolipidaemic derivatives decrease hepatic synthesis and secretion of triacylglycerol by decreased diacylglycerol acyltransferase activity and stimulation of fatty acid oxidation, Biochem J, 343, 191, 10.1042/bj3430191 · DOI
  64. Pineda, 1999, Peroxisome proliferator-activated receptor alpha in metabolic disease, inflammation, atherosclerosis and aging., Curr Opin Lipidol, 10, 151, 10.1097/00041433-199904000-00009 · DOI · Paper page
  65. Randle, 1998, Regulatory interactions between lipids and carbohydrates: the glucose fatty acid cycle after 35 years, Diabetes Metab Rev, 14, 263, 10.1002/(SICI)1099-0895(199812)14:4<263::AID-DMR233>3.0.CO;2-C · doi:10.1002/(sici)1099-0895(199812)14:4<263::aid-dmr233>3.0.co;2-c
  66. Malasanos, 1991, Biological effects of omega-3 fatty acids in diabetes mellitus, Diabetes Care, 14, 1160, 10.2337/diacare.14.12.1160 · DOI
  67. De Caterina, 2000, Fatty acid modulation of endothelial activation, Am J Clin Nutr, 71, 213S, 10.1093/ajcn/71.1.213S · DOI · Paper page
  68. Mori, 2000, Effect of ω3 fatty acids on oxidative stress in humans: GCMS measurement of urinary F2-isoprostane excretion, Redox Report, 5, 45, 10.1179/rer.2000.5.1.45 · DOI · Paper page

Cited by

See all 226

Metadata

Authors
Mori, T. A., & Woodman, R. J.
Venue
Current Opinion in Clinical Nutrition & Metabolic Care
Published
2006-03
Volume
9
Issue
2
Pages
95-104
ISSN
1363-1950 (ISSN-L)
OpenAlex
W2007259227
Cited by
226
References
19
FWCI
13.81
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The independent effects of eicosapentaenoic acid and docosahexaenoic acid on cardiovascular risk factors in humans. https://app.cochat.ai/papers/10.1097/01.mco.0000214566.67439.58
The paper
Mori, T. A., & Woodman, R. J. (2006). The independent effects of eicosapentaenoic acid and docosahexaenoic acid on cardiovascular risk factors in humans. Current Opinion in Clinical Nutrition & Metabolic Care. https://doi.org/10.1097/01.mco.0000214566.67439.58

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.